KRAS

Targeting the ‘Activated State’ KRAS: Discovery of the Highly Cooperative PROTAC Degrader ACBI4

by
Targeting the 'Activated State' KRAS: Discovery of the Highly Cooperative PROTAC Degrader ACBI4

Hello everyone, this week I am sharing an article published in JACS titled “Identification of a Highly Cooperative PROTAC Degrader Targeting GTP-Loaded KRAS(On) Alleles.” The corresponding authors are Professors Alessio Ciulli and Kirsten McAulay from the University of Dundee, along with Peter Ettmayer from Boehringer Ingelheim. Their research primarily focuses on the mechanism of action … Read more

New Hope for Long-Term Survival in Late-Stage Patients: Overview of Five Major Targeted Drugs and Clinical Trials for Non-Small Cell Lung Cancer

by
New Hope for Long-Term Survival in Late-Stage Patients: Overview of Five Major Targeted Drugs and Clinical Trials for Non-Small Cell Lung Cancer

EGFR In the Chinese patient population, EGFR is the most common driver gene mutation type in non-small cell lung cancer and is also one of the gene types with relatively good efficacy. However, even for this type of non-small cell lung cancer, there are still some “blind spots” in targeted therapy, such as certain difficult-to-treat … Read more